Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

New Covid Variant Raises Fear: Stocks to Own to Buck the Trend

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/bioneer-corp" target="_blank" data-smartkarma-citation="entities:11487:1" rel="noopener">Bioneer Corp (064550 KS) </a>is the only Korean biotech company that provides a total solution for molecular diagnostic, including raw materials, test equipment, and kits. Its molecular diagnostic business is a source of stable cash flow, while its probiotic business is on a high growth trajectory. The company’s new drug pipeline has enabled business expansion in treatment area.</li>
<li>As importance of early prevention and diagnosis is growing with the easing of social distancing, travel, and other restrictions, Bioneer is developing and supplying molecular diagnostic kits and equipment used for diagnosis of various diseases, including COVID as well as product development for life science research. Bioneer is expanding production capacity by 8x and preparing to secure large-scale supply contracts in domestic and international markets.</li>
<li>Through a well-diversified and comprehensive business model, Bioneer aims to become a global bio-health company, with a presence in diagnosis, treatment, and prevention of diseases based on the original technology in the genetic field. This insight has mainly analyzed the strength of each of the business line with and beyond COVID.   </li>
</ul>



Bioneer Corp (064550 KS) is the only Korean biotech company that provides a total solution for molecular diagnostic, including raw materials, test equipment, and kits. Its molecular diagnostic business is a source of stable cash flow, while its probiotic business is on a high growth trajectory. The company’s new drug pipeline has enabled business expansion in treatment area.
As importance of early prevention and diagnosis is growing with the easing of social distancing, travel, and other restrictions, Bioneer is developing and supplying molecular diagnostic kits and equipment used for diagnosis of various diseases, including COVID as well as product development for life science research. Bioneer is expanding production capacity by 8x and preparing to secure large-scale supply contracts in domestic and international markets.
Through a well-diversified and comprehensive business model, Bioneer aims to become a global bio-health company, with a presence in diagnosis, treatment, and prevention of diseases based on the original technology in the genetic field. This insight has mainly analyzed the strength of each of the business line with and beyond COVID.   


Bioneer Corp (064550 KS): Gaining Strength ‘With COVID’ and ‘Beyond COVID’; Poised to Rebound